“The Pulmonary Hypertension Associated with Interstitial Lung Disease Market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Pulmonary Hypertension Associated with Interstitial Lung Disease pipeline products will significantly revolutionize the Pulmonary Hypertension Associated with Interstitial Lung Disease market dynamics”
The Pulmonary Hypertension Associated with Interstitial Lung Disease market report provides current treatment practices, Pulmonary Hypertension Associated with Interstitial Lung Disease emerging drugs, market share of individual therapies, and current and forecasted 7MM Pulmonary Hypertension Associated with Interstitial Lung Disease market size from 2019 to 2032. The report also covers current Pulmonary Hypertension Associated with Interstitial Lung Disease treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Key Takeaways from the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Report
- The increase in Pulmonary Hypertension Associated with Interstitial Lung Disease Market Size is a direct consequence of expected launch of potential therapies, along with increasing awareness and development of novel therapies.
- The leading companies working in the Pulmonary Hypertension Associated with Interstitial Lung Disease Market include Insmed Incorporated, Liquidia Technologies Inc., Bayer, Bellerophon Therapeutics, and others.
- Promising Pulmonary Hypertension Associated with Interstitial Lung Disease Pipeline Therapies in the various stages of development include Treprostinil Palmitil Inhalation Powder, L606 inhalation suspension, Riociguat (Adempas, BAY63-2521), and others.
- July 2023: Insmed Incorporated announced a study of Phase 2 & 3 Clinical Trials for Treprostinil Palmitil Inhalation Powder. The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with PH-ILD.
- August 2023: Insmed Incorporated announced a study of Phase 2 Clinical Trials for Treprostinil Palmitil. The primary objective of this study is to evaluate the safety and tolerability of treprostinil palmitil inhalation powder (TPIP) compared with placebo.
- August 2023: Liquidia Technologies Inc. announced a study of Phase 3 Clinical Trials for L606 inhalation suspension. This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population; also evaluate the steady-state pharmacokinetics (PK) of L606 as compared to Tyvaso, effects on exercise ability, quality of life, and treatment satisfaction with L606.
Discover more about therapies set to grab major Pulmonary Hypertension Associated with Interstitial Lung Disease Market Share @ Pulmonary Hypertension Associated with Interstitial Lung Disease Market Size
Pulmonary Hypertension Associated with Interstitial Lung Disease Overview
Pulmonary hypertension (PH) is an important complication of interstitial lung disease (ILD), characterized by an elevation in pulmonary artery pressures of varying etiologies, which may result in substantial morbidity. PH is clinically classified into five groups, defined by the World Symposium on PH, according to different pathological findings between groups, including the underlying cause of disease, clinical presentation, and hemodynamic characteristics.
Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology Segmentation in the 7MM
- Total Pulmonary Hypertension Associated with Interstitial Lung Disease Diagnosed Prevalent Cases
- Pulmonary Hypertension Associated with Interstitial Lung Disease Type-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology Trends @ Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiological Insights
Pulmonary Hypertension Associated with Interstitial Lung Disease Market Insights
The appearance of increased pulmonary pressures is uniformly a harbinger of poor outcomes, and so is the case in PH-ILD. Advances in therapeutic options have led to an urgency to look for PH in ILD patients. In the usual care of ILD patients, specific symptoms, physical exam results, and laboratory and imaging findings can point to additional testing, such as echocardiography. However, further studies are needed to overcome several unmet needs on the therapeutic and diagnostic front.
Pulmonary Hypertension Associated with Interstitial Lung Disease Market Size
DelveInsight’s analysts estimate that the market is expected to show positive growth, mainly attributed by increased prevalence and the expected launch of novel therapies, such as TPIP, INOpulse, and others during the forecast period (2023–2032).
To know more about Pulmonary Hypertension Associated with Interstitial Lung Disease Treatment options, visit @ Pulmonary Hypertension Associated with Interstitial Lung Disease Drugs
Pulmonary Hypertension Associated with Interstitial Lung Disease Emerging Therapy Assessment
Pulmonary Hypertension Associated with Interstitial Lung Disease Companies across the globe are working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Insmed Incorporated, Bellerophon Therapeutics, Liquidia Corporation, and others are developing drugs for the treatment of PH-ILD.
Learn more about the Pulmonary Hypertension Associated with Interstitial Lung Disease Pipeline Therapies in clinical trials @ Pulmonary Hypertension Associated with Interstitial Lung Disease Market Landscape
Scope of the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Report
- Coverage- 7MM
- Study Period- 2023-2032
- Pulmonary Hypertension Associated with Interstitial Lung Disease Companies- Insmed Incorporated, Liquidia Technologies Inc., Bayer, Bellerophon Therapeutics, and others.
- Pulmonary Hypertension Associated with Interstitial Lung Disease Pipeline Therapies- Treprostinil Palmitil Inhalation Powder, L606 inhalation suspension, Riociguat (Adempas, BAY63-2521), and others
- Pulmonary Hypertension Associated with Interstitial Lung Disease Market Dynamics: Pulmonary Hypertension Associated with Interstitial Lung Disease Market Drivers and Barriers
- Pulmonary Hypertension Associated with Interstitial Lung Disease Market Access and Reimbursement, Unmet Needs, and Future Perspectives
Discover more about Pulmonary Hypertension Associated with Interstitial Lung Disease Drugs in development @ Pulmonary Hypertension Associated with Interstitial Lung Disease Ongoing Clinical Trials Analysis
Table of Content
1. Key Insights
2. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Report Introduction
3. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Overview at a Glance
4. Executive Summary of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
5. Key Events
6. Disease Background and Overview of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
7. Epidemiology and Patient Population of PH-ILD
8. Patient Journey
9. Pulmonary Hypertension Associated with Interstitial Lung Disease Marketed drugs
10. Pulmonary Hypertension Associated with Interstitial Lung Disease Emerging Drugs
11. PH-ILD: Seven Major Market Analysis
12. Pulmonary Hypertension Associated with Interstitial Lung Disease Unmet Needs
13. Pulmonary Hypertension Associated with Interstitial Lung Disease SWOT Analysis
14. Key Opinion Leaders’ Views
15. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Reimbursement and Market Access
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking